Experience with the use of daptomycin in patients with infective endocarditis oncohematological and cardiosurgical profile


Cite item

Full Text

Abstract

The study of the effectiveness of antibacterial therapy with daptomycin in the treatment of gram-positive infection in 44 patients with infectious endocarditis was conducted. Primary infectious endocarditis developed in 15 patients, including 3 patients who were observed for oncohematological diseases (acute leukemia, myelodysplastic syndrome). In 29 patients secondary endocarditis was diagnosed, among the secondary forms of the disease endocarditis prevailed after cardiac surgery. In 32 patients, the bacteriological study revealed the pathogen. Among the identified pathogens included: 7 patients - methicillin-sensitive S. aureus,5 - methicillin-resistant S. aureus, 3 - methicillin-resistant S. Epidermidis in 9 - Enterococcus faecalis, 8 - Streptococcus bovis. All patients were prescribed antibacterial therapy with daptomycin, in monotherapy and in combination with beta-lactams, and surgical treatment was also performed. The average dose of daptomycin was 6,9±0,8 mg/kg/ day, the average duration of treatment 26,2±9,4 days. In 20 (45,4%) patients, repeated surgical treatment with a positive result were performed, there were no fatal outcomes among the operated patients. Of the 44 patients treated with daptomycin, 5 died (due to the inability to provide surgical treatment), in 1 case an early relapse of infectious endocarditis developed, in other cases there was a positive dynamics on the background of treatment, the resolution of infectious complications. No cases of resistance of the infectious agent to daptomycin have been reported. Thus, the use of daptomycin in the treatment of gram-positive infections in patients with cardiosurgical and oncohematological profile is justified and shows good results in tolerability and effectiveness both in monotherapy and in combination with other antibiotics.

About the authors

VV GG Khubulava

Военно-медицинская академия им. С.М. Кирова

Email: vmeda-nio@mil.ru
Санкт-Петербург

V P Turin

Военно-медицинская академия им. С.М. Кирова

Email: vmeda-nio@mil.ru
Санкт-Петербург

A V Koltsov

Национальный медико-хирургический центр им. Н.И. Пирогова

Москва

A Ya Fisun

Военно-медицинская академия им. С.М. Кирова

Email: vmeda-nio@mil.ru
Санкт-Петербург

A Ya Fisun

Военно-медицинская академия им. С.М. Кирова

Email: vmeda-nio@mil.ru
Санкт-Петербург

References

  1. Дехнич, А.В. Даптомицин: обзор фармакологических, клини- ческих и микробиологических параметров / А.В. Дехнич, А.И. Данилов // Клин. микробиол. и антимикробная хими- отерапия. - 2010. - № 12 (4). - С. 295-313.
  2. Baddour, L.M. Clinical practice. Infections of cardiovascular implantable electronic devices / L.M. Baddour, Y.M. Cha, W.R. Wilson // N. Engl. J. Med. - 2012. - № 367. - P. 842-849.
  3. Canton, R. A potential role for daptomycin in enterococcal infections: what is the evidence? / R. Canton, R. Chaves, A. Johnson // J. Antimicrob. Chemother. - 2010. - № 65. - P. 1126-1136.
  4. Fowler, V.G. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus / V.G. Fowler [et al.] // N. Engl. J. Med. - 2006. - № 355. - P. 653-665.
  5. Gaca, J.G. Outcomes for endocarditis surgery in North America: a simplified risk scoring system / J.G. Gaca [et al.] // J. Thorac. Cardiovasc. Surg. - 2011. - № 141. - P. 98-106.
  6. Guleri, A. Effectiveness and safety of daptomycin in patients with infective endocarditis undergoing heart valve replacement: a subgroup analysis from real-world data / A. Guleri, R. Utili, P. Dohmen, K. Hamed // Ther. Adv. Infect. Dis. - 2017. - № 4 (2).- P. 41-47.
  7. Habib, G. 2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC) / G. Habib [et al.] // Eur. Heart. J.- 2015. - № 364 (4). - P. 3075-3128.
  8. Kang, D.H. Early surgery versus conventional treatment for infective endocarditis / D.H. Kang [et al.] // N. Engl. J. Med. - 2012. - № 366. - P. 2466-2473.
  9. Nadrah, K. Antibiotic combinations with daptomycin for treatment of Staphylococcus aureus infections / K. Nadrah, F. Strle // Chemotherapy Research and Practice. - 2011. - № 2011. - Р.10.
  10. Popov, A.F. Daptomycin as a possible new treatment option for surgical management of Methiillin-resistant Staphylococcus aureus sternal wound infection after cardiac surgery / A.F. Popov, J.D. Schmitto, T. Tirilomis // J. Cardiothorac Surg. - 2010. - № 5 (1). - Р. 57.
  11. Rabkin, D.G. Long-term outcome for the surgical treatment of infective endocarditis with a focus on intravenous drug users / D.G. Rabkin [et al.] // Ann. Thorac. Surg. - 2012. - № 93. - P. 51-57.
  12. Safdar, N. In vivo pharmacodynamic activity of daptomycin / N. Safdar, D. Andes, W.A. Craig // Antimicrob Agents Chemother. - 2004. - № 48. - P. 63-68.
  13. Sohail, M.R. Infective endocarditis complicating permanent pacemaker and implantable cardioverterdefibrillator infection / M.R. Sohail [et al.] // Mayo Clin. Proc. - 2008. - № 83. - P. 46-53.
  14. Thuny, F. Impact of cerebrovascular complications on mortality and neurologic outcome during infective endocarditis: a prospective multicentre study / F. Thuny [et al.] // Eur. Heart J. - 2007. - № 28. - P.1155-1161.

Copyright (c) 2018 Khubulava V.G., Turin V.P., Koltsov A.V., Fisun A.Y., Fisun A.Y.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies